ASIA JOBS
The Premier Source for latest jobs and trends in
Pharma, healthcare & biotechnology & research
We connect millions of readers to new trends &
opportunities worldwide.
Trusted by the Business of Biotech & Health Sciences, University
Professors, Companies and Other Research Organizations
For Job Seekers For Job Employer
Search job by location Post Unlimited Jobs
Create multiple job alerts Activate & deactivate jobs
Customize job search according Candidate Search
to industry, Career type Download candidates resume
Receive industry updates
Expert’s thoughts from leaders
Please visit: https://www.biospectrumjobs.com
For more information Email us at: [email protected]
WE’RE CELEBRATING.
A NEW ANTIBODY
FAILED TO FAIL.
The US FDA has granted a Breakthrough Therapy designation to the first anti-TIGIT
therapy for use in NSCLC in combination with PD-L1 blockade. TIGIT expression in
paraffin-embedded non-small cell lung cancer is observed using TIGIT (E5Y1W) XP®
Rabbit mAb #99567.
OUR PROCESS — YOUR SUCCESS.
As a privately held company founded and led by
active research scientists, we understand your
needs as a researcher. Like you, we only want to use
products that are specific and deliver reproducible
results. We validate every one of our thousands of
antibodies and research products in-house. If any
product fails to meet our stringent standards, we
won’t sell it. But when one passes, it’s a big deal. For
over 20 years, researchers have trusted CST to help
them achieve experimental success. You can, too.
www.cellsignal.com
© 2022 Cell Signaling Technology, Inc. Cell Signaling Technology, CST, and XP are trademarks or registered trademarks of Cell Signaling Technology, Inc. 22-BCH-13880-MAR22
The words you are searching are inside this book. To get more targeted content, please make full-text search by clicking here.
Targeting Optimal DRUG DELIVERY
In recent years, several innovations have emerged around long-acting formulations and medical device development to improve patient compliance. Consequently, the growing need for controlled
drug release coupled with technological advancements in pharmacology is promoting the adoption
of novel drug delivery systems (NDDS). It is now crucial for Asia Pacific (APAC) drug formulators to learn and act upon these advances in therapeutic modalities that address long-standing
bioavailability, dosage, and ingestion challenges of drug components to remain competitive in the global market. Simultaneously, it’s essential to optimise the therapeutic efficacy and safety profiles of a drug by regulating dosage parameters, while DDS plays an important role in administering
drugs, vaccines, and therapeutic agents. Optimising these techniques enhance the performance
efficacy ratio of medications by economically managing therapeutics assets. Let’s examine recent
advancements in drug delivery modalities that are greatly
encouraging stakeholders’ collaboration among innovators, manufacturers, investors, and contract development and manufacturing companies CDMOs)
who are capitalising on competitive advantages.
Discover the best professional documents and content resources in AnyFlip Document Base.
Search